Zentalis Pharmaceuticals, Inc. ZNTL
We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, or PROC. We believe that our DENALI (ZN-c3-005) Part 2 clinical trial of azenosertib in patients with Cyclin E1-positive PROC, if successful, has the potential to support an accelerated approval, subject to U.S. Food and Drug Administration, or FDA, review. Azenosertib also has broad franchise potential beyond Cyclin E1-positive PROC. We exclusively in-license or solely own worldwide development and commercialization rights to azenosertib.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $67.4M | $0 | $0 | — | — | — | — |
| R&D | $107.3M | $167.8M | $189.6M | $172.7M | $175.6M | $84.9M | $38.4M | — |
| SG&A | $37.7M | $87.1M | $64.4M | $54.6M | $40.9M | $33.9M | $8.5M | — |
| Total operating expenses | $152.8M | $258.6M | $299.5M | $227.3M | $216.5M | $118.8M | $46.8M | — |
| Operating income | -$152.8M | -$191.2M | -$299.5M | -$227.3M | -$216.5M | -$118.8M | -$46.8M | — |
| Pre-tax income | -$136.6M | -$165.7M | -$292.9M | -$237.6M | -$166.4M | -$118.1M | -$46.4M | — |
| Income tax | $442.0K | $177.0K | $601.0K | $469.0K | $297.0K | $444.0K | $15.0K | — |
| Net income | -$137.1M | -$165.9M | -$292.3M | -$236.8M | -$158.7M | -$117.8M | -$45.7M | — |
| EPS, basic | -1.91 | -2.33 | -4.47 | -4.48 | -3.72 | -4.19 | — | — |
| EPS, diluted | -1.91 | -2.33 | -4.47 | -4.48 | -3.72 | -4.19 | -8.16 | — |
| Shares, diluted (wtd. avg.) | 71.9M | 71.1M | 65.4M | 52.9M | 42.7M | 28.1M | 5.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $36.0M | $33.9M | $28.0M | $45.7M | $62.6M | $56.3M | $67.5M | $25.2M |
| Short-term investments | $209.9M | $318.0M | $454.9M | — | — | — | — | — |
| Receivables | $0 | $5.0M | $0 | — | $4.0K | $417.0K | $140.0K | — |
| Total current assets | $253.2M | $386.1M | $496.7M | $451.9M | $350.8M | $345.1M | $68.9M | — |
| Property, plant and equipment | $2.8M | $4.7M | $5.8M | $7.7M | $8.1M | $1.1M | $501.0K | — |
| Goodwill | — | $0 | $3.7M | $3.7M | $3.7M | $3.7M | $3.7M | — |
| Total assets | $289.0M | $430.3M | $551.7M | $539.3M | $454.5M | $365.6M | $87.5M | — |
| Accounts payable | $7.2M | $7.4M | $14.9M | $11.2M | $11.6M | $8.7M | $4.3M | — |
| Total current liabilities | $36.6M | $52.7M | $69.4M | $56.6M | $43.9M | $28.6M | $14.9M | — |
| Total liabilities | $72.8M | $93.2M | $114.3M | $105.3M | $90.0M | $32.2M | $19.1M | — |
| Retained earnings | -$1.19B | -$1.05B | -$888.6M | -$596.4M | -$359.6M | -$200.8M | -$83.0M | — |
| Total equity | $216.2M | $337.2M | $437.4M | $434.0M | $364.5M | $333.4M | -$73.3M | $32.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$125.2M | -$170.9M | -$207.8M | -$163.8M | -$154.1M | -$86.8M | -$39.1M | — |
| Depreciation and amortisation | $739.0K | $1.3M | $1.4M | $1.4M | $544.0K | $160.0K | $111.0K | — |
| Stock-based compensation | $20.7M | $67.3M | $54.8M | $46.8M | $35.7M | $23.1M | $617.0K | — |
| Capital expenditure | $0 | $221.0K | $583.0K | $2.5M | $6.1M | $758.0K | $352.0K | — |
| Investing cash flow | $131.6M | $176.6M | -$44.5M | -$114.2M | -$18.1M | -$284.8M | -$352.0K | — |
| Financing cash flow | -$4.3M | $108.0K | $237.3M | $261.0M | $178.5M | $360.4M | $81.8M | — |
| Buybacks | $10.0M | $0 | $0 | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001725160-26-000027.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $0 | $67.4M | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$45.7M | -$117.8M | -$158.7M | -$236.8M | -$292.3M | -$165.9M | -$137.1M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |